IT IS IMPOSSIBLE to completely wipe off racism from the world, feels fast bowling great Michael Holding, who would "bruise his knee" to the grave if he was still an active player but doesn't want anyone to take the gesture as "a tick-in-the-box exercise".
Holding was speaking on Sky Sports' The Cricket Show on the first death anniversary of African-American George Floyd, who died at the hands of a white police office in the Minnesota last year.
"You will always have racism, always have racists. Getting rid of racism totally is like saying you are going to get rid of crime totally. It is impossible," Holding said during a panel discussion that also had former England captain Nasser Hussain and woman international Ebony Rainford-Brent.
"The less crime you have in your society, the less racism you have in your society, the better off the world is as we go ahead," he added.
Holding feels that the gesture of "taking a knee" should be organic rather a "tick the box" exercise but he doesn't believe in telling people what their choices should be.
"I am not going to tell people they must take a knee - I am not here to tell people what they need to do. I don't want people to take it as a tick-in-the-box exercise.
"You must want to support the cause, you must be willing to understand and see that something is wrong and this is the worldwide accepted way of showing support for the cause," he said.
The West Indian great, who now lives in the United Kingdom, said not everyone can understand the challenges that black people endure through their lives.
"People don't understand what it is like to come under that sort of pressure throughout your entire life. Some people say things and don't even realise what they are saying or the effect it might have on a black person.
"It's something they get accustomed to saying," the 67-year-old, one of the most respected cricketing voices across the globe, said.
Holding didn't hide the raging anger he has felt at times while interacting with people who resort to casual racism which can be equally hurtful.
"As a black person, when you hear certain people say certain things it burns inside. I have had many occasions when people have said something or treated me a particular way when I think to myself 'are they just rude or are they racist?
"Is it because I am black that they are treating me this way or is it because they don't know any better because they are rude?," he said.
Holding agreed that there could be times that the intent of a comment is not racist but for a black person, who has suffered, that's the first thing that comes to mind during interactions.
"I have no idea - but as a black person the first thing that comes to your mind, because of the constant battle with racism, is racism. Sometimes you are wrong, sometimes the person is not racist, but it builds up inside of you and the first thought is racism."
Holding believes that UK hasn't done enough to weed out racism.
"But, right now, I don't think we have made enough ground, especially in the UK. I am going to be blunt now. I don't see enough action in the UK.
"I see a lot of action in the US. Big corporations in the US putting up millions and millions of dollars toward programmes to levelling the playing field," he said.
"Apart from Sky, who are we seeing in the UK doing anything? There is a little bit of lip service every now and again but what really positive signs of action have we seen?" he asked.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.